No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

5/6

Eli Lilly

Alchemab

Therapeutics

ATLX-1282

αUNC5C mA9433b

Neurology

ALS

Preclinical

415

2

5/14

GSK

Boston

Efimosfermin

alfa

FGF21R modulator

Metabolic

Disorder

MASH, Liver diseases

Phase 2

1,200

3

5/14

AbbVie

ADARx

Pharmaceuticals

n/d

siRNA program

Neurology,

Immunology,

Oncology

n/d

n/d

335

4

5/14

Novo Nordisk

Septerna

n/d

GPCR targeting program

Metabolic

Disorder

Obesity,

T2D,

Cardio-metabolic diseases

n/d

2,200

5

5/15

Eli Lilly

Rznomics

n/d

RNA-editing therapies using

trans-splicing ribozyme platform

Others

Hearing loss

n/d

1,300

6

5/19

CRISPR

Therapeutics

Sirius Therapeutics

SRSD107

FXI siRNA

Cardiovascular Disease

Thrombosis

Phase 1

n/d

7

5/19

Pfizer

3S Bio

SSGJ-707

VEGF x PD-1 BsAbs

Oncology

NSCLC,

Colorectal Cancer,

Endometrial Cancer,

Ovarian Cancer

Phase 2

6,050

8

5/21

Genentech

Orionis Biosciences

Allo-GlueTM

Small-molecule monovalent glue

n/d

n/d

n/d

2,105

9

5/26

Servier

BioNova

Pharmaceuticals

BN104

Menin inhibitor

Oncology

Acute myeloid leukemia,
Acute promyelocytic leukemia,
Acute lymphocytic leukemia

Phase 1/2

n/d

10

5/27

Biogen

City Therapeutics

n/d

RNAi engineering tech

Neurology

CNS diseases

n/d

1,000

11

5/29

Astellas

Pharma

Evopoint

Biosciences

XNW27011

CLDN18.2 ADC

Oncology

Solid tumors; GI cancers

Phase 1/2

1,340

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

5/16

BioMarin

Inozyme

INZ-701

ENPP1 gene modulator

Others

ENPP1 deficiency

Phase 3

270

2

5/19

Sanofi

Vigil Neuroscience

VG-3927

TREM2 agonist

Neurology

Alzheimer’s diseases

Phase 1

256

3

5/27

Eli Lilly

SiteOne Therapeutics

STC-004

Nav1.8 inhibitor

Neurology

Pain

Phase 2

1,000